Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma

[1]  Niko Välimäki,et al.  CTCF/cohesin-binding sites are frequently mutated in cancer , 2015, Nature Genetics.

[2]  L. Chin,et al.  Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. , 2015, The Journal of clinical investigation.

[3]  J. Larkin,et al.  Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.

[4]  N. Hayward,et al.  Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma , 2014, Nature Communications.

[5]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[6]  R. Levine,et al.  Genetic alterations of the cohesin complex genes in myeloid malignancies. , 2014, Blood.

[7]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[8]  Frank McCormick,et al.  Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.

[9]  T. Waldman,et al.  Cohesin gene mutations in tumorigenesis: from discovery to clinical significance , 2014, BMB reports.

[10]  A. Losada,et al.  Cohesin in cancer: chromosome segregation and beyond , 2014, Nature Reviews Cancer.

[11]  V. Corces,et al.  CTCF: an architectural protein bridging genome topology and function , 2014, Nature Reviews Genetics.

[12]  K. Döhner,et al.  Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. , 2014, Blood.

[13]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[14]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[15]  Dennis C. Friedrich,et al.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.

[16]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.

[17]  N. Rosen,et al.  Tumor adaptation and resistance to RAF inhibitors , 2013, Nature Medicine.

[18]  S. Miyano,et al.  The landscape of somatic mutations in Down syndrome–related myeloid disorders , 2013, Nature Genetics.

[19]  L. Cantley,et al.  Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. , 2013, Molecular cell.

[20]  L. Cantley,et al.  Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma , 2013, Proceedings of the National Academy of Sciences.

[21]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[22]  M. Rubin,et al.  Frequent truncating mutations of STAG2 in bladder cancer , 2013, Nature Genetics.

[23]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[24]  A. Valencia,et al.  Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy , 2013, Nature Genetics.

[25]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[26]  Yan Cui,et al.  CTCFBSDB 2.0: a database for CTCF-binding sites and genome organization , 2012, Nucleic Acids Res..

[27]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[28]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[29]  Hongtao Yu,et al.  Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer , 2011, Science.

[30]  K. Flaherty,et al.  BRAF targeted therapy changes the treatment paradigm in melanoma , 2011, Nature Reviews Clinical Oncology.

[31]  G. Felsenfeld,et al.  Specific Sites in the C Terminus of CTCF Interact with the SA2 Subunit of the Cohesin Complex and Are Required for Cohesin-Dependent Insulation Activity , 2011, Molecular and Cellular Biology.

[32]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[33]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[34]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[35]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[36]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[37]  L. Chin,et al.  Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. , 2009, Molecular cell.

[38]  T. Golub,et al.  Modeling genomic diversity and tumor dependency in malignant melanoma. , 2008, Cancer research.

[39]  C. Pritchard,et al.  A critical function for B-Raf at multiple stages of myelopoiesis. , 2005, Blood.